Preprint2020

Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 phase 3 study

DOI 10.1101/2020.05.01.20087668 ↗ Europe PMC, retrieved 4 November 2026

Published: 6 May 2020
Citations: 0
Type: Preprint

These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Trials 1

Builds on itCapecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine NCT00440167 ↗

Other versions 1

Journal version (canonical)Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translationa… DOI 10.1038/s41416-020-01029-7 ↗